TET2 and acute myeloid leukemia: To evaluate if the enhanced effect of 5-AZA treatment in TET2-deficient AML would also hold true in vivo, mice were transplanted with CebpaΔ/p30Tet2Δ/Δ or CebpaΔ/p30Tet2+/+ AML blasts and treated with 5-AZA for three consecutive days after disease establishment (Fig. 6a).